PHENOM
5.5.2021 09:02:13 CEST | Business Wire | Press release
Phenom , the No. 1 provider of Talent Experience Management (TXM) solutions, has been recognized as a Strategic Leader in the 2021 Fosway 9-Grid™ for Talent Acquisition . Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to meet the needs of complex enterprise-scale customers. Additionally, these solutions achieve higher levels of customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005153/en/
The Fosway Group 9-Grid™ report for Talent Acquisition indicates the relative position of solutions and providers in the European talent acquisition system space. Analyzing data from the pandemic-altered market, the 2021 report also indicates how well software solutions scaled and performed for customers during last year’s volatility.
The report identified several key market and solution trends, including:
- THE GREAT REBOARD: Companies that lost jobs last year are pivoting to better recruitment technology to prepare for strategic, efficient rehiring.
- CANDIDATE EXPERIENCE: Transparent communication and agile decision-making underlie positive candidate experiences for both hires and non-hires.
- ARTIFICIAL INTELLIGENCE: Enterprises must leverage AI and automation in the hiring process to remain competitive.
- DIVERSITY, EQUITY & INCLUSION : Employers are realizing that diversity, equity and inclusion commitments must be a centerpiece in their HR strategies.
- VIDEO EXPERIENCES : Live video’s role in hiring will last beyond the pandemic, as companies realize it will be an efficient, authentic way to find best-fit candidates.
- INTERVIEW SCHEDULING : Chatbot and AI reduce friction across the scheduling process, generating more meaningful interactions between candidates and recruiters.
- TALENT MARKETPLACE : The most effective solutions need to include gigs, reskilling and upskilling for mutual employer/employee growth.
- COLLABORATIVE HIRING : Increasing communication between recruiter and hiring manager workflows is encouraged through integrations with Microsoft Teams and Slack.
“Phenom’s focus on disrupting the candidate and hiring experiences, has resonated strongly with the market,” said David Wilson, CEO of Fosway. “Rapid growth in adoption in enterprise organisations, as well as expanded physical presence and multiple market acquisitions is further accelerating its success in Europe and globally. All of these warrant Phenom’s increased rating as a Strategic Leader for Talent Acquisition in 2021.”
In 2020, the Phenom platform was adopted by 25,000 recruiters, talent marketers and hiring managers — helping them hire over 2 million people and engage over 3 million employees.
The Phenom platform automates administrative tasks and personalizes experiences, generating more impactful moments throughout the talent journey. As a result, candidates find the right job faster; employees learn and evolve; recruiters discover best-fit talent with efficiency and scale; and managers make stronger data-driven decisions to build their future teams.
Kuehne+Nagel, a global logistics company and Phenom customer, continues to see new value in the Phenom platform every day.
“Through Phenom, we’ve been able to strengthen our centralized recruitment activities per hemisphere, build an external career site and adapt it to local markets, implement a CRM — and now level up our employee experience — to build the most sophisticated talent acquisition ecosystem there is to offer,” said Sandra Aasma, global HR systems expert at Kuehne+Nagel.
“As Phenom continues to expand across EMEA, we’re honored to be one of the first-ever Strategic Leaders in Fosway’s Talent Acquisition grid,” said Jeff Carey, senior vice president of international business at Phenom. “Our new position on the Fosway 9-grid™ signals that enterprises routinely pick Phenom — galvanized by our sophisticated AI-powered platform and steadfast commitment to customers. By constantly upgrading and launching new products, we always stay at the front of a rapidly evolving HR technology market.”
Over 100 companies across the EMEA market have adopted Phenom’s platform to upgrade their talent experiences. As demand for Talent Experience Management has spiked, Phenom recently acquired two Europe-based companies and opened an office in Munich to complement its European headquarters in Rotterdam. With over 100 employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom, Phenom continues to solidify EMEA’s importance within the company’s ultimate growth strategy.
To learn more about Phenom’s Strategic Leader position, please visit their blog .
To see Fosway’s full analysis, check out their 2021 9-grid™ .
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom